Patent ID: 6986890

Claim:
A method for treating a disease in which the morbid state progresses by abnormal angiogenesis, comprising administering to a human or an animal in need of such treatment an effective amount of a recombinant monoclonal antibody selected from the group consisting of a human chimeric antibody and an antibody fragment, said recombinant monoclonal antibody specifically reacting with the human VEGF receptor Flt-1, wherein the recombinant monoclonal antibody binds to an epitope present in a region of the 1st to 338th positions from the N-terminal amino acid including a signal sequence of the human VEGF receptor Flt-1, said recombinant monoclonal antibody comprising an antibody H chain variable region (V region) and an antibody L chain V region of a monoclonal antibody, and H chain constant region (C region) and L chain C region of a human antibody, said H chain V region comprising an amino acid sequence of SEQ ID NO:88, and said L chain V region comprising an amino acid sequence of SEQ ID NO:89.